Related Experiment Video
Updated: Sep 14, 2025

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
Real-life Use of IV Naxitamab for Children With Relapsed/Refractory Neuroblastoma
Iris Fried1, Michael Weintraub1, Dalia Waldman2
1Pediatric Hematology Oncology unit, Shaare Tzedek medical center, Jerusalem, Israel.
None:
The anti-GD2 antibody Naxitamab requires complicated pain management due to significant adverse effects (AEs). Herein, we report the safety and feasibility of a simplified administration protocol. Between November 2021 and July 2023, 102 Naxitamab infusions were administered at Shaare Zedek Hospital with ketamine as the only analgesic drug during Naxitamab infusion. Pain was controlled in all the cases. Other grade 3-4 AEs, occurred in 10/102 infusions (10%), and none of the patients stopped Naxitamab due to infusion-related AEs. Single-agent ketamine is safe and effective for Naxitamab-infusion-related pain. Thus, its use is feasible in multiple clinical settings. Significant infusion-related AEs after the completion of the 3rd treatment cycle are rare.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
Related Concept Videos
Treatment Resistant Cancers
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists